Antibodies binding LAG3 and methods of treatment using them
AssigneesBeijing Mabworks Biotech Co., Ltd., Beijing Mabridge Biopharmaceutical Co., Ltd.
InventorsWenqi Hu, Jiangmei Li, Feng Li
Life of this patent
Estimating the term…
Abstract
An isolated monoclonal antibody or an antigen-binding portion thereof that specifically binds human LAG3. A nucleic acid molecule encoding the antibody or antigen-binding portion thereof, an expression vector, a host cell and a method for expressing the antibody or antigen-binding portion thereof are also provided. The present disclosure further provides an immuneconjugate, a bispecific molecule, a chimeric antigen receptor, and a pharmaceutical composition comprising the antibody or antigen-binding portion thereof thereof, as well as a treatment method using the same.
Claims20
An isolated monoclonal antibody, or an antigen-binding portion thereof, binding to LAG3, comprising a heavy chain variable region comprising a VH CDR1 region, a VH CDR2 region and a VH CDR3 region, and a light chain variable region comprising a VL CDR1 region, a VL CDR2 region and a VL CDR3 region, wherein the VH CDR1 region, the VH CDR2 region, the VH CDR3 region, the VL CDR1 region, the VL CDR2 region and the VL CDR3 region comprise the amino acid sequences set forth in (1) SEQ ID NOs:
- 1, 2, 3, 5, 6 and 7, respectively;
- (2) SEQ ID NOs:
- 1, 2, 4, 5, 6 and 8, respectively;
- or (3) SEQ ID NOs:
- 21, 22, 23, 24, 25 and 26, respectively.
Dependencies are inferred from the claim text.